Entering text into the input field will update the search result below

Aerie Pharmaceuticals, Inc. (AERI) CEO Vicente Anido on Q1 2020 Results - Earnings Call Transcript

May 08, 2020 12:22 AM ETAerie Pharmaceuticals, Inc. (AERI)
SA Transcripts profile picture
SA Transcripts

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Q1 2020 Earnings Conference Call May 6, 2020 5:00 PM ET

Company Participants

Ami Bavishi - Director of Investor Relations

Vince Anido - Chairman and Chief Executive Officer

Tom Mitro - President and Chief Operating Officer

Rich Rubino - Chief Financial Officer

Conference Call Participants

Annabel Samimy - Stifel

Ken Cacciatore - Cowen and Company

Serge Belanger - Needham & Company

Louise Chen - Cantor

Jason Gerberry - Bank of America

Esther Rajavelu - Oppenheimer

Greg Fraser - SunTrust

Dan Clark - Mizuho Securities

Elliot Wilbur - Raymond James


Good afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the Aerie Pharmaceuticals First Quarter 2020 Earnings Conference Call. At this time all participants are in a listen-only mode. [Operator Instructions] Today's conference call is being recorded.

It is now my pleasure to turn the floor over to Aerie's Director of Investor Relations, Ami Bavishi. Please go ahead, Ami.

Ami Bavishi

Thank you, Chris. Good afternoon and thank you for joining us. With us today are Vince Anido, Aerie's Chairman and Chief Executive Officer; Tom Mitro, Aerie's President and Chief Operating Officer; Rich Rubino, Aerie's Chief Financial Officer; and John LaRocca, Aerie's General Counsel. Today's call is also being webcast live on our website, investors.aeriepharma.com, and it will be available for replay as indicated in our press release.

Now for forward-looking statements and non-GAAP financial measures. On this call, we will make certain forward-looking statements, including statements, forecasts and observations regarding our future financial and operating performance, potential impacts of the COVID-19 pandemic and our observations regarding ongoing operating expenses and net revenue per bottle.

These statements will include observations associated with our commercialization of Rhopressa and Rocklatan in the United States. They will also include plans and expectations regarding the success, timing and cost

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.